These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20394038)

  • 21. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
    Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
    Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
    Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract]   [Full Text] [Related]  

  • 23. Estimating treatment effects for individual patients based on the results of randomised clinical trials.
    Dorresteijn JA; Visseren FL; Ridker PM; Wassink AM; Paynter NP; Steyerberg EW; van der Graaf Y; Cook NR
    BMJ; 2011 Oct; 343():d5888. PubMed ID: 21968126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
    Scheen AJ
    Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JUPITER strikes earth.
    Fuster V; Bansilal S
    Nat Clin Pract Cardiovasc Med; 2009 Mar; 6(3):159. PubMed ID: 19234496
    [No Abstract]   [Full Text] [Related]  

  • 26. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 27. The Jupiter trial: key findings, controversies, and implications.
    Nissen SE
    Curr Cardiol Rep; 2009 Mar; 11(2):81-2. PubMed ID: 19236822
    [No Abstract]   [Full Text] [Related]  

  • 28. [JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
    Lubsen J
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):216-7. PubMed ID: 19271438
    [No Abstract]   [Full Text] [Related]  

  • 29. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.
    Sondermeijer BM; Boekholdt SM; Rana JS; Kastelein JJ; Wareham NJ; Khaw KT
    Eur Heart J; 2013 May; 34(18):1350-7. PubMed ID: 23449857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Sniderman AD
    Lancet; 2009 Jul; 374(9683):25; author reply 26-7. PubMed ID: 19577690
    [No Abstract]   [Full Text] [Related]  

  • 33. The JUPITER Trial: responding to the critics.
    Ridker PM; Glynn RJ
    Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837
    [No Abstract]   [Full Text] [Related]  

  • 34. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is hsCRP Back on Board? Implications from the JUPITER Trial.
    Koenig W
    Clin Chem; 2009 Feb; 55(2):216-8. PubMed ID: 19074517
    [No Abstract]   [Full Text] [Related]  

  • 36. [JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
    Håkansson J
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1460-1. PubMed ID: 19579433
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of high-sensitivity CRP to predict first cardiovascular events.
    Stahl HD
    Lancet; 2007 Apr; 369(9569):1259-1260. PubMed ID: 17434399
    [No Abstract]   [Full Text] [Related]  

  • 38. Another look at the results of the JUPITER trial.
    Kappagoda CT; Amsterdam EA
    Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
    de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M
    Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
    Slejko JF; Page RL; Sullivan PW
    Curr Med Res Opin; 2010 Oct; 26(10):2485-97. PubMed ID: 20828360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.